OCTOBER-DECEMBER IN SUMMARY Net sales for the period amounted to KSEK - (-).Result for the period amounted to KSEK -32,844 (-47,880).Earnings and diluted earnings per share totaled SEK -0.16 (-0.58).Immunicum
10.02.2022 - Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on the prevention of cancer recurrence and addressing hard-to-treat tumors, will publish its financial results for the fourth quarter and full year ended December 31, 2021 .
Immunicum AB ("Immunicum" publ; IMMU.ST), a biopharmaceutical company focused on the prevention of cancer recurrence and addressing hard-to-treat tumors, will publish its financial results for the fourth
Investegate announcements from Immunicum AB, Immunicum AB: Invitation to Immunicum s Full-Year 2021 Review and Pipeline and Strategy Outlook Held as a Hybrid Event on February 17, 2022
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 08, 2022 (GLOBE NEWSWIRE) Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat